Sign in Subscribe

PharmGKB Staff

PharmGKB Demo at U-PGx Summer School

PharmGKB recently held a demonstration of the PharmGKB website as part of the U-PGx Summer School in Bonn, Germany. Scientists, clinicians and pharmacists attending the summer school heard from Dr. Rachel Huddart, one of our Scientific Curators, and were introduced to the various types of information found on the PharmGKB

New PharmGKB pathways for ondansetron and tropisetron

Ondansetron and tropisetron are 5-HT3 receptor antagonists used to treat nausea and vomiting and are commonly prescribed to patients who have undergone surgery or who are receiving chemotherapy. They are both covered by a CPIC guideline which can be accessed on the CPIC website.PharmGKB has released two new pathways

Curators' Favorite Papers

The growing number of individuals using direct to consumer (DTC) genetic tests has also led to an increase in physicians counseling patients on their results. In an effort to reveal the perspectives of physicians who receive these “unsolicited genomic results” (UGR), the Electronic Medical Records and Genomics (eMERGE) Network has

Curators' Favorite Papers

A critical component of pharmacogenetic/pharmacogenomics (PGx) implementation into clinical care is the integration of PGx data in clinical decision support (CDS) and electronic health records (EHRs). A new article in the journal Human Molecular Genetics (Genomics and electronic health record systems) discusses the benefits of, and current challenges to,

Dr. Francis Collins discusses All of Us on CBS This Morning

The National Institutes of Health (NIH) director Dr. Francis Collins appeared on CBS This Morning to promote the All of Us program, a part of the Precision Medicine Initiative, which launches this Sunday, May 6th. When asked about what it hopes to accomplish, he explained:“Do you ever feel when

Curators' Favorite Papers

The first paper comes from the journal Pharmacogenomics (Clinical pharmacogenetics: how do we ensure a favorable future for patients?) and it discusses the factors that have impeded the implementation of pharmacogenomic (PGx) testing into routine clinical care. Randomized clinical trials (RCT) are the current gold-standard for clinical research for new

The Clobazam Pathway on the Cover of Pharmacogenetics and Genomics

One of our newest pathways, the Clobazam Pathway, Pharmacokinetics, is featured on the cover of the April issue of the journal Pharmacogenetics and Genomics. PharmGKB Scientific Curator Dr. Rachel Huddart is the first author on this pathway. Clobazam is a benzodiazepine and is used primarily as an anti-epileptic. The primary

Curator's Favorite Papers

Genetics has been shown to have a profound effect on response to treatment in patients with major depressive disorder (MDD) and may account for as much as 42% of the variability in treatment response, according to some studies. In addition, personality traits, as defined by “the Big-Five" (openness, conscientiousness,

PharmGKB FAQs: How do I read a clinical annotation?

Clinical annotations are written to summarize associations between variants and drug response and are based on annotations of published literature. As an example, please refer to this clinical annotation for rs4149056 in the gene SLCO1B1 and the drug simvastatin. Clinical annotations consist of 3 main parts: 1. Genotype/diplotype-based summaries

Curators' Favorite Papers

The first paper, by A. Ahmed et al. in the journal Clinical Pharmacology and Therapeutics (Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder), discusses pharmacogenetic (PGx) testing in the context of depression. In a pilot study, 1,002 out of 1,013 (99%) subjects had an actionable